Shenzhen Weiguang Biological Products Co Ltd (002880) - Net Assets
Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has net assets worth CN¥2.48 Billion CNY (≈ $362.30 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.67 Billion ≈ $536.64 Million USD) and total liabilities (CN¥1.19 Billion ≈ $174.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002880 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.48 Billion |
| % of Total Assets | 67.51% |
| Annual Growth Rate | 24.96% |
| 5-Year Change | 36.73% |
| 10-Year Change | 382.81% |
| Growth Volatility | 35.48 |
Shenzhen Weiguang Biological Products Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's net assets have evolved over time, based on quarterly financial data. See Shenzhen Weiguang Biological Products Co liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
The table below shows the annual net assets of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025. For live valuation and market cap data, see Shenzhen Weiguang Biological Products Co stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $357.80 Million |
+8.95% |
| 2024-12-31 | CN¥2.24 Billion ≈ $328.40 Million |
+9.71% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.34 Million |
+9.54% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.28 Million |
+4.43% |
| 2021-12-31 | CN¥1.79 Billion ≈ $261.68 Million |
+10.13% |
| 2020-12-31 | CN¥1.62 Billion ≈ $237.61 Million |
+12.08% |
| 2019-12-31 | CN¥1.45 Billion ≈ $212.00 Million |
+10.95% |
| 2018-12-31 | CN¥1.31 Billion ≈ $191.08 Million |
+8.53% |
| 2017-12-31 | CN¥1.20 Billion ≈ $176.06 Million |
+137.57% |
| 2016-12-31 | CN¥506.44 Million ≈ $74.11 Million |
+28.63% |
| 2015-12-31 | CN¥393.71 Million ≈ $57.61 Million |
+27.47% |
| 2014-12-31 | CN¥308.86 Million ≈ $45.20 Million |
+37.96% |
| 2013-12-31 | CN¥223.88 Million ≈ $32.76 Million |
+65.84% |
| 2012-12-31 | CN¥135.00 Million ≈ $19.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Weiguang Biological Products Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14990.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.40 Billion | 58.16% |
| Other Components | CN¥1.01 Billion | 41.84% |
| Total Equity | CN¥2.41 Billion | 100.00% |
Shenzhen Weiguang Biological Products Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Burelle SA
PA:BUR
|
$736.23 Million |
|
Alerus Financial Corp
NASDAQ:ALRS
|
$736.27 Million |
|
Friend Co Ltd
SHG:605050
|
$736.31 Million |
|
Shanghai Zhongyida Co Ltd A
SHG:600610
|
$736.53 Million |
|
Isgec Heavy Engineering Limited
NSE:ISGEC
|
$736.07 Million |
|
Lahav LR Real Estate Ltd
TA:LAHAV
|
$735.64 Million |
|
Era Co Ltd
SHE:002641
|
$735.61 Million |
|
Guangdong Biolight Meditech Co Ltd
SHE:300246
|
$735.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Weiguang Biological Products Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,211,425,331 to 2,412,386,071, a change of 200,960,740 (9.1%).
- Net income of 246,320,740 contributed positively to equity growth.
- Dividend payments of 65,727,025 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥246.32 Million | +10.21% |
| Dividends Paid | CN¥65.73 Million | -2.72% |
| Other Changes | CN¥20.37 Million | +0.84% |
| Total Change | CN¥- | 9.09% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Weiguang Biological Products Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.01x to 2.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.79 | CN¥22.18 | x |
| 2013-12-31 | CN¥1.32 | CN¥22.18 | x |
| 2014-12-31 | CN¥1.81 | CN¥22.18 | x |
| 2015-12-31 | CN¥2.31 | CN¥22.18 | x |
| 2016-12-31 | CN¥2.97 | CN¥22.18 | x |
| 2017-12-31 | CN¥6.07 | CN¥22.18 | x |
| 2018-12-31 | CN¥5.76 | CN¥22.18 | x |
| 2019-12-31 | CN¥6.38 | CN¥22.18 | x |
| 2020-12-31 | CN¥7.07 | CN¥22.18 | x |
| 2021-12-31 | CN¥7.80 | CN¥22.18 | x |
| 2022-12-31 | CN¥8.12 | CN¥22.18 | x |
| 2023-12-31 | CN¥8.88 | CN¥22.18 | x |
| 2024-12-31 | CN¥9.75 | CN¥22.18 | x |
| 2025-12-31 | CN¥10.64 | CN¥22.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Weiguang Biological Products Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.21%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.45%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.55x
- Recent ROE (10.21%) is below the historical average (20.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 52.92% | 23.81% | 0.45x | 4.93x | CN¥57.94 Million |
| 2013 | 39.70% | 25.02% | 0.50x | 3.18x | CN¥66.49 Million |
| 2014 | 32.55% | 22.21% | 0.59x | 2.49x | CN¥69.66 Million |
| 2015 | 31.71% | 24.92% | 0.59x | 2.17x | CN¥85.48 Million |
| 2016 | 30.26% | 27.07% | 0.62x | 1.80x | CN¥102.58 Million |
| 2017 | 12.86% | 24.82% | 0.45x | 1.14x | CN¥34.43 Million |
| 2018 | 12.00% | 22.77% | 0.47x | 1.12x | CN¥26.06 Million |
| 2019 | 11.83% | 20.86% | 0.52x | 1.09x | CN¥26.55 Million |
| 2020 | 11.87% | 21.05% | 0.49x | 1.14x | CN¥30.02 Million |
| 2021 | 11.61% | 22.64% | 0.45x | 1.13x | CN¥28.56 Million |
| 2022 | 6.38% | 17.59% | 0.26x | 1.40x | CN¥-66.56 Million |
| 2023 | 10.86% | 20.85% | 0.36x | 1.43x | CN¥17.22 Million |
| 2024 | 11.46% | 21.07% | 0.36x | 1.49x | CN¥32.37 Million |
| 2025 | 10.21% | 19.45% | 0.34x | 1.55x | CN¥5.08 Million |
Industry Comparison
This section compares Shenzhen Weiguang Biological Products Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,212,589,599
- Average return on equity (ROE) among peers: 2.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Weiguang Biological Products Co Ltd (002880) | CN¥2.48 Billion | 52.92% | 0.48x | $736.11 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more